Skip to main content
Michael Carducci, MD, Oncology, Baltimore, MD, Johns Hopkins Hospital

MichaelAnthonyCarducciMD

Oncology Baltimore, MD

AEGON Professor of Prostate Cancer Research, Associate Director for Clinical Research, Member, Miller-Coulson Academy of Clinical Excellence

Dr. Carducci is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Carducci's full profile

Already have an account?

Summary

  • Dr. Michael Carducci is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center, and Sibley Memorial Hospital. He received his medical degree from Wayne State University School of Medicine and has been in practice 29 years. He specializes in hematologic oncology and is experienced in urologic oncology, and palliative medicine.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1992 - 1995
  • University of Colorado
    University of ColoradoResidency, Internal Medicine, 1988 - 1992
  • Wayne State University School of Medicine
    Wayne State University School of MedicineClass of 1988

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 2012 - 2024
  • MD State Medical License
    MD State Medical License 1992 - 2024
  • VA State Medical License
    VA State Medical License 2022 - 2024
  • CO State Medical License
    CO State Medical License 1990 - 1993
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Other

Press Mentions

  • Intervention to Improve Patient-Physician Communication May Improve Black Patient Participation in Clinical Trials, Study Led by Karmanos Researcher
    Intervention to Improve Patient-Physician Communication May Improve Black Patient Participation in Clinical Trials, Study Led by Karmanos ResearcherFebruary 27th, 2023
  • Dramatic Results Seen with Bone-Protecting Agents in Prostate Cancer Patients
    Dramatic Results Seen with Bone-Protecting Agents in Prostate Cancer PatientsJune 5th, 2019
  • Trials Back Earlier Use of Androgen Receptor Inhibitors
    Trials Back Earlier Use of Androgen Receptor InhibitorsJune 3rd, 2019
  • Join now to see all

Grant Support

  • Phase I Clinical Trials Of New Anti-Cancer Targeted TherapiesNational Cancer Institute2008–2012
  • DSMNational Cancer Institute2006–2010
  • Phase I Clinical Trials Of New Anti-Cancer Targeted TherNational Cancer Institute2003–2007
  • Foreign Accrual For U01ca70095 - 2006 Load.National Cancer Institute2006
  • Restoration Of Gene Function In Prostate CancerNational Cancer Institute2003
  • Phase I Trials Of Anticancer AgentsNational Cancer Institute2001–2002
  • Phase I Trial Of Oral Phenylbutyrate In Solid TumorsNational Center For Research Resources2000–2002
  • Dose/Pharmacokinetics Of ABT 627 In AdenocarcinomaNational Center For Research Resources2000–2002
  • Multiple Dose Study Of Safety Of ABT 627National Center For Research Resources1998–2002
  • A Randomized Controlled Phase II Clinical Trial Of ModulDivision Of Cancer Prevention And Control1999–2000
  • Phenylbutyrate Bioactivity Assessment In Prostate CancerNational Cancer Institute1997–2000
  • Gene Therapy For Prostate CancerNational Cancer Institute1996–2000
  • Continuous Infusion Phenylbutyrate Given For 120 HRS Every 21 DaysNational Center For Research Resources1997

Hospital Affiliations